CHINA RESOURCES MEDICAL HOLDINGS COMPANY LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.23 HKD | +0.95% |
|
+2.42% | -12.24% |
| 26/04 | China Resources Medical's 2023 Profit Slides | MT |
| 19/03 | China Resources Medical Holdings Company Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 19 July 2024 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's profit outlook over the next few years is a strong asset.
- The company is in a robust financial situation considering its net cash and margin position.
- Its low valuation, with P/E ratio at 8.63 and 6.56 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The stock, which is currently worth 2024 to 0.45 times its sales, is clearly overvalued in comparison with peers.
- The company's share price in relation to its net book value makes it look relatively cheap.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -12.24% | 696M | - | ||
| -15.68% | 16.57B | B+ | ||
| +4.50% | 12.51B | B | ||
| +4.48% | 11.69B | B+ | ||
| +6.18% | 10.36B | B+ | ||
| +26.21% | 8.38B | B | ||
| -2.87% | 7.75B | A- | ||
| +20.39% | 7.12B | D | ||
| +3.39% | 6.6B | B- | ||
| +46.01% | 4.54B | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 1515 Stock
- Ratings China Resources Medical Holdings Company Limited